OncoMatch/Clinical Trials/NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Is NCT05963074 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ibrutinib and Venetoclax for leukemia, lymphocytic, chronic, b-cell.
Treatment: Ibrutinib · Venetoclax — The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Oncology Institute Clinical Research · Cerritos, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- SLO Oncology and Hematology Health Center · San Luis Obispo, California
- Providence Medical Foundation · Santa Rosa, California
- PIH Health Hospital · Whittier, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05963074 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages